WHY: Making the world disease free. HOW: We find the real drug lead candidate by capturing the synergistic effect of mutations (epistasis). WHAT: We have developed the Data-Centric innov’SAR AI industrial platform for our partners. PEACCEL is definitely the ONLY company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of "hit rate". We can solve the "1+1=10" challenge! The innov'SAR core approach is interpolative, extrapolative and predicts outside-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 billion mutants per day. PEACCEL can produce massive amounts of Synthetic data to train its ML/DL platform. Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality. PEACCEL is built around the 6 pillars - P6 -: PLATFORM, PUBLICATIONS, PATENTS, PARTNERSHIPS, PRODUCTS and PEOPLE  We have developed the innov'SAR PLATFORM, including 4 modules : 1- innov’SAR core: For the optimization of polypeptides (peptides, proteins, enzymes, antibodies, VHHs) 2- RAS module: For evaluating combination of Drugs (FDCs) in various diseases 3- automlSAR: this tool tests in parallel >135 algorithms, is agnostic with respect to the data set and can be combined with innov’SAR core & RAS module 4- GraphMut: Graph-based visualization tool of relations between the mutations of protein sequence variants and activity variations  15 PUBLICATIONS in the last 2 years  Strong worldwide PATENTS (on technology using FFT), with more to come  Robust PARTNERSHIPS with top notch KOLs worldwide  Focus on high value PRODUCTS  Highly skilled PEOPLE in high-tech fields.

Biotechnology Modeling Pharmaceuticals Science Innovation Drug Discovery Machine Learning Deep Learning Enzymes Chemical Industry Antibodies Data Centric Green Chemistry Ert Life Cycle Management Strategic Partnership Vhh Protein Engineering Protein Optimization Regulatory Authorities Synthetic Data Ai For Life Sciences